PAVM Logo

PAVmed Inc. (PAVM) 

NASDAQ
Market Cap
$11.07M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
659 of 775
Rank in Industry
85 of 99

Largest Insider Buys in Sector

PAVM Stock Price History Chart

PAVM Stock Performance

About PAVmed Inc.

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, …

Insider Activity of PAVmed Inc.

Over the last 12 months, insiders at PAVmed Inc. have bought $0 and sold $0 worth of PAVmed Inc. stock.

On average, over the past 5 years, insiders at PAVmed Inc. have bought $96,666 and sold $377,824 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 100,000 shares for transaction amount of $62,320 was made by Glennon Michael J (director) on 2022‑12‑07.

List of Insider Buy and Sell Transactions, PAVmed Inc.

2022-12-07Purchasedirector
100,000
0.1128%
$0.62$62,320-32.26%
2022-12-06Purchasedirector
88,000
0.1032%
$0.64$56,082-31.07%
2022-12-05Purchasedirector
62,000
0.0713%
$0.69$42,606-37.26%
2021-03-18PurchaseChairman and CEO
7,500
0.0102%
$4.31$32,324+16.12%
2020-11-25Sale10 percent owner
33,203
0.0686%
$1.96$65,048+158.16%
2020-11-24Sale10 percent owner
53,036
0.11%
$2.00$105,876+154.27%
2020-11-19Sale10 percent owner
75,211
0.1596%
$1.83$137,418+184.27%
2020-11-18Sale10 percent owner
24,789
0.0502%
$1.78$44,164+178.02%
2020-05-29Sale10 percent owner
131,082
0.2912%
$1.98$259,477+5.03%
2020-05-28Sale10 percent owner
69,839
0.162%
$2.06$143,666+5.56%
2019-05-24PurchasePresident & CFO
5,000
0.0184%
$1.09$5,429+1.87%
2019-05-23PurchaseChairman and CEO
30,000
0.1072%
$1.09$32,850-1.80%
2018-08-28PurchaseChairman and CEO
30,000
0.1084%
$1.18$35,400-12.20%
2018-06-08Sale10 percent owner
18,300
0.0967%
$1.04$19,032+10.49%
2018-06-01Sale10 percent owner
532,255
2.6899%
$0.97$516,287+12.76%
2017-11-20PurchaseChairman and CEO
950
0.0075%
$4.70$4,465-66.22%
2017-11-17PurchaseChairman and CEO
601
0.0045%
$4.37$2,626-65.14%
2017-09-15PurchaseChairman and CEO
2,600
0.0238%
$8.77$22,814-76.88%
2017-09-13PurchaseChairman and CEO
300
0.0022%
$6.88$2,065-76.78%
2017-09-12PurchaseChairman and CEO
100
0.0007%
$6.66$666-76.15%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
First Manhattan Co.$909,500.004.51425,000+112.5%+$481,500.00<0.01
The Vanguard Group$643,158.003.19300,541-0.68%-$4,419.10<0.0001
BlackRock$160,312.000.7974,912-0.01%-$21.40<0.0001
Geode Capital Management$135,626.000.6763,360+15.04%+$17,728.13<0.0001
Valeo Financial Advisors LLC$39,089.000.2221,1290%+$0<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.